Medy-Tox
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Medy-Tox sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Medy-Tox: 5 sponsored US clinical trials, none currently recruiting.
Medy-Tox sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 5 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lateral Canthal Lines, with 2 trials.
Upper-quartile sponsor footprint
Medy-Tox sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
NCT04157686
MT10109L in the Treatment of Glabellar Lines
NCT03795922
MT10109L in the Treatment of Lateral Canthal Lines
NCT03785145
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
NCT03732833
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
NCT03721016
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 5 |
Therapeutic Areas
How the Medy-Tox archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 5 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Lateral Canthal Lines (2 trials), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Medy-Tox: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Medy-Tox sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Medy-Tox page
5 registered trials is a research-attention snapshot, not an endorsement of Medy-Tox or any single study.
- None of Medy-Tox's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lateral Canthal Lines is the condition Medy-Tox studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lateral Canthal Lines trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Medy-Tox pipeline card: 5 registered trials from official public datasets.Report a data error.